Show simple item record

IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity [preprint]

dc.contributor.authorMonir, Ejemel
dc.contributor.authorLi, Qi
dc.contributor.authorHou, Shurong
dc.contributor.authorSchiller, Zachary
dc.contributor.authorWallace, Aaron
dc.contributor.authorAmcheslavsky, Alla
dc.contributor.authorYilmaz, Nese Kurt
dc.contributor.authorToomey, Jacqueline R.
dc.contributor.authorSchneider, Ryan
dc.contributor.authorCavacini, Lisa
dc.contributor.authorKlempner, Mark S.
dc.contributor.authorSchiffer, Celia A.
dc.contributor.authorWang, Yan
dc.date2022-08-11T08:08:24.000
dc.date.accessioned2022-08-23T15:54:10Z
dc.date.available2022-08-23T15:54:10Z
dc.date.issued2020-05-15
dc.date.submitted2020-07-22
dc.identifier.citation<p>Ejemel M, Li Q, Hou S, Schiller ZA, Wallace AL, Amcheslavsky A, Yilmaz NK, Toomey JR, Schneider R, Close BJ, Chen DY, Conway HL, Mohsan S, Cavacini LA, Klempner MS, Schiffer CA, Wang Y. IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity. bioRxiv [Preprint]. 2020 May 15:2020.05.15.096719. doi: 10.1101/2020.05.15.096719. PMID: 32511396; PMCID: PMC7263543. <a href="https://doi.org/10.1101/2020.05.15.096719">Link to article on publisher's site</a></p>
dc.identifier.doi10.1101/2020.05.15.096719
dc.identifier.pmid32511396
dc.identifier.urihttp://hdl.handle.net/20.500.14038/29495
dc.description<p>Full author list omitted for brevity. For the full list of authors, see article.</p>
dc.description.abstractCOVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32511396&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1101/2020.05.15.096719
dc.rightsThe copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
dc.subjectmicrobiology
dc.subjectbiochemistry
dc.subjectSARS-CoV-2
dc.subjectmucosal immunity
dc.subjectantibody
dc.subjectCOVID-19
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectBiochemistry
dc.subjectImmunity
dc.subjectImmunology of Infectious Disease
dc.subjectImmunoprophylaxis and Therapy
dc.subjectImmunotherapy
dc.subjectInfectious Disease
dc.subjectMicrobiology
dc.subjectVirus Diseases
dc.titleIgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunity [preprint]
dc.typePreprint
dc.source.journaltitlebioRxiv
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=2730&amp;context=faculty_pubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/faculty_pubs/1718
dc.identifier.contextkey18616852
refterms.dateFOA2022-08-23T15:54:10Z
html.description.abstract<p>COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity or as a therapeutic has yet been developed to SARS-CoV-2. In this study we discover and characterize a cross-reactive human IgA monoclonal antibody, MAb362. MAb362 binds to both SARS-CoV and SARS-CoV-2 spike proteins and competitively blocks hACE2 receptor binding, by completely overlapping the hACE2 structural binding epitope. Furthermore, MAb362 IgA neutralizes both pseudotyped SARS-CoV and SARS-CoV-2 in human epithelial cells expressing hACE2. SARS-CoV-2 specific IgA antibodies, such as MAb362, may provide effective immunity against SARS-CoV-2 by inducing mucosal immunity within the respiratory system, a potentially critical feature of an effective vaccine.</p>
dc.identifier.submissionpathfaculty_pubs/1718
dc.contributor.departmentSchiffer Lab
dc.contributor.departmentDepartment of Biochemistry and Molecular Pharmacology
dc.contributor.departmentMassBiologics


Files in this item

Thumbnail
Name:
2020.05.15.096719v1.full.pdf
Size:
628.4Kb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record